In a strong public warning, the Central Drugs Standard Control Organization (CDSCO) has clarified that no cosmetic product is permitted to be administered via injection by consumers, professionals, or aesthetic clinics. The notice, issued by the Drugs Controller General (India), Dr Rajeev Raghuvanshi, comes amid the rapid growth of beauty clinics offering skin-lightening shots, anti-ageing injections, and intravenous "glow drips" across Indian cities.

Simply put, a bride in Lucknow spends ₹15,000 on a so-called "glutathione glow injection" days before her wedding. An aesthetic clinic promises radiant skin and a flawless appearance. However, India's top drug regulator has now clarified that such a procedure cannot legally qualify as a cosmetic treatment.

The regulator reminded consumers and industry stakeholders that cosmetics are defined under the Drugs and Cosmetics Act, 1940, as products intended to be rubbed, poured, sprinkled, sprayed or otherwise applied externally to the human body for cleansing, beautifying or enhancing appearance. Injectable preparations do not fall under that definition.

The most striking line in the notice states: "No cosmetic is permitted to be used as an injection by consumers/professionals/aesthetic clinics."

The warning addresses a booming beauty market fuelled by social media trends, celebrity endorsements and influencer promotions. Hundreds of online advertisements claim that injectable products can whiten skin, reverse ageing, remove pigmentation or provide instant radiance. However, CDSCO has made it clear that cosmetics cannot be promoted as treatments for diseases, skin disorders, hair loss or medical conditions.

Health experts say the distinction is more than a legal technicality. It is also a safety issue.

Glutathione, one of the most commonly marketed ingredients in beauty injections, is a naturally occurring antioxidant produced by the body. Antioxidants help protect cells from damage. Yet dermatology studies have repeatedly noted that evidence supporting intravenous glutathione for skin whitening remains limited, while concerns persist regarding potential side effects and unregulated use.

The World Health Organization and drug safety authorities worldwide have long warned that any injectable product carries risks if quality, sterility and medical supervision are not assured. Even a small injection can potentially trigger allergic reactions, infections, contamination, blood clots or damage to organs, such as the kidneys and liver. A blood clot simply means a lump of blood forming inside a vessel, which can block normal circulation and become dangerous.

CDSCO has also warned against misleading claims, false labelling and the use of prohibited ingredients. Under the Cosmetics Rules, 2020, products must not convey false or deceptive information to consumers.

Industry observers say the notice marks one of the clearest regulatory statements yet on the blurred line between beauty and medicine. While consumers increasingly seek quick cosmetic fixes, regulators are signalling that appearance-enhancing promises can't bypass scientific evidence or legal safeguards.

The public has been encouraged to report suspected violations to CDSCO and state licensing authorities. As injectable beauty treatments become more visible on social media feeds and clinic menus, the regulator's message is straightforward: a cosmetic is not a medicine, and a cosmetic injection is a medical treatment.